TMS Co.,Ltd.

4891 TSE Pharmaceuticals Pharmaceutical
TSE Growth
¥118.00
-2.48%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Low debt: debt-to-equity of 0.03.
  • Current assets comfortably cover current liabilities (current ratio 30.42).

!Watch-points

  • Return on equity is on the lower side at -25.9%.
  • Return on capital employed is on the lower side at -25.2%.
  • Sales growth has been slow over five years (about 0% a year).

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreDistress zone
0.01

In Altman’s study, scores in this range were associated with a higher incidence of financial distress.

Computed without the market-value term.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap¥55億
Current Price¥ 118.00
High / Low¥ 166.00 / 92.00
Stock P/E-7.34
Book Value¥ 60.14
Dividend Yield0%
ROCE-25.15%
ROE-25.90%
Debt to Equity0.03
Current Ratio30.42
P/B Ratio2.236882
EPS¥ -16.08
Compounded Sales Growth
10 Years
5 Years 0.00%
3 Years
TTM
Compounded Profit Growth
10 Years
5 Years
3 Years
TTM
Stock Price CAGR
10 Years
5 Years
3 Years
1 Year
Return on Equity
10 Years
5 Years
3 Years
Last Year -25.90%
Educational data only. Not a recommendation to buy, sell or hold any security.